QLC Biotech
Last updated Jun 18, 2026
Evidence Sources
2
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
5
Clinical Programs
0
Confidence Coverage
72%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Oncology
- Prostate Cancer
Highest priority development: Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
Regulatory precedent
Why this matters: sets a safety guidance precedent in the same sub-indication (prostate cancer) as QLC Biotech.
Competitive pressure: Low
Portfolio impact: Low
Evidence coverage: 72%
Active Signals
1
Investigate Priority
0
Opportunity Score
16
Buyer Quality
8 · Mid-Market
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 18, 2026Score 16Phase Ib/II Trial of QLC5508 and QLH12016 in Advanced Prostate Cancer
Oncology · Prostate Cancer
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and DeathModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and AnswersModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancerModerate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — INQOVI (SUPPL)Moderate Confidence · 72%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to QLC Biotech right now?
- Which regulatory precedents should QLC Biotech monitor in Oncology and Prostate Cancer?
- How does Emerging Clinical Trials in Oncology compare to the nearest competitive programs?
- What signals require immediate investigation for QLC Biotech?
- Summarize the strategic implications of recent developments for QLC Biotech.
- Where is the greatest uncertainty in QLC Biotech's competitive positioning?